News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
120,251 Results
Type
Article (6051)
Company Profile (28)
Press Release (114172)
Section
Business (35783)
Career Advice (160)
Deals (5949)
Drug Delivery (10)
Drug Development (6569)
Employer Resources (20)
FDA (3554)
Job Trends (2533)
News (53043)
Policy (4568)
Tag
Academia (489)
Alliances (12109)
Alzheimer's disease (298)
Approvals (3551)
Artificial intelligence (47)
Bankruptcy (53)
Best Places to Work (2081)
Biotechnology (17)
Breast cancer (24)
Cancer (225)
Cardiovascular disease (18)
Career advice (143)
Cell therapy (17)
Clinical research (4886)
Collaboration (103)
COVID-19 (525)
C-suite (19)
Data (125)
Diagnostics (5641)
Earnings (11127)
Employer resources (20)
Events (15079)
Executive appointments (51)
FDA (3648)
Funding (82)
Gene therapy (31)
GLP-1 (59)
Government (811)
Healthcare (3529)
Infectious disease (544)
Interviews (21)
IPO (2101)
Job creations (492)
Job search strategy (134)
Layoffs (29)
Legal (663)
Lung cancer (23)
Manufacturing (34)
Medical device (2765)
Medtech (2767)
Mergers & acquisitions (3866)
Metabolic disorders (26)
Neuroscience (334)
NextGen Class of 2024 (1035)
Non-profit (793)
Northern California (247)
Opinion (31)
People (10231)
Phase I (1618)
Phase II (2081)
Phase III (1837)
Pipeline (53)
Postmarket research (233)
Preclinical (726)
Prostate cancer (21)
Radiopharmaceuticals (119)
Rare diseases (29)
Real estate (994)
Regulatory (3327)
Research institute (514)
Resumes & cover letters (20)
Southern California (170)
Startups (752)
United States (2083)
Vaccines (46)
Date
Today (28)
Last 7 days (136)
Last 30 days (579)
Last 365 days (5924)
2024 (5410)
2023 (6924)
2022 (11190)
2021 (10711)
2020 (10267)
2019 (7983)
2018 (6092)
2017 (6137)
2016 (6149)
2015 (6946)
2014 (5188)
2013 (4567)
2012 (4855)
2011 (5104)
2010 (4406)
Location
Africa (150)
Arizona (44)
Asia (5942)
Australia (1458)
California (476)
Canada (195)
China (24)
Colorado (28)
Connecticut (37)
Europe (16603)
Florida (61)
Georgia (31)
Illinois (72)
Japan (14)
Maine (20)
Maryland (69)
Massachusetts (280)
Michigan (54)
Minnesota (77)
Missouri (17)
New Hampshire (17)
New Jersey (93)
New Mexico (16)
New York (200)
North Carolina (155)
Northern California (247)
Ohio (22)
Pennsylvania (73)
South America (201)
Southern California (170)
Texas (85)
Utah (47)
Virginia (21)
Washington State (41)
Wisconsin (15)
120,251 Results for "blue earth diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA®
Blue Earth Diagnostics Highlights Presentations on POSLUMA® at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held June 8 to 11, 2024, in Toronto, Canada.
May 29, 2024
·
10 min read
Pharm Country
Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer
Blue Earth Diagnostics announced highlights from clinical studies conducted by its collaborators at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, 2024.
June 10, 2024
·
9 min read
Business
SHINE Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility
SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals.
June 6, 2024
·
3 min read
Business
Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
September 24, 2024
·
7 min read
Press Releases
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies
October 30, 2024
·
5 min read
Press Releases
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data
October 8, 2024
·
5 min read
Pharm Country
Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference
Blue Earth Therapeutics today announced that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference. The event will be held in New York, N.Y., on March 1, 2024.
February 28, 2024
·
3 min read
Drug Development
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA ® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU.
January 25, 2024
·
11 min read
Pharm Country
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177 Lu-rhPSMA-10.1 for Treatment of Prostate Cancer.
April 8, 2024
·
7 min read
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on POSLUMA® (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) at the upcoming ASCO GU 2024 Genitourinary Cancers Symposium (ASCO GU).
January 16, 2024
·
7 min read
1 of 12,026
Next
